The 29th Conference on Retroviruses and Opportunistic Infections (CROI), held from February 12 to 16, 2022, is currently planned to include options for virtual or in-person participation. More than 4 hours of core content will be available live to both in-person and virtual attendees each day (as indicated on the schedule below).

In-Person

In addition to the 4.5 hours of core content, the in-person component (hosted at the Colorado Convention Center in Denver, Colorado, USA) features additional sessions and networking opportunities.

Virtual

Virtual attendees can access the core 4.5 hours of live content, beginning at 8:30 AM Mountain Time (Denver, CO, USA) each day. Convert to Your Local Time. Some in-person sessions will be available as on-demand content to virtual attendees at a later time.

8:30 AM MT - 12:30 PM MT
In-Person
Virtual
SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

  • ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 – Theodora Hatziioannou, Rockefeller University, New York, NY, USA
  • ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY – Penny Moore, University of the Witwatersrand, Johannesburg, South Africa
  • ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC – Carlos del Rio, Emory University, Atlanta, GA, USA
  • ADVANCES IN BIOMEDICAL PREVENTION OF HIV – Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES – Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA
8:30 AM MT - 10:45 AM MT
In-Person
Virtual
OPENING SESSION

MARTIN DELANEY PRESENTATION

WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, PrEPster, London, United Kingdom

The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.

BERNARD FIELDS LECTURE

Dan H. Barouch, Beth Israel Deaconess Medical Center, Boston, MA, USA

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

N’GALY-MANN LECTURE

HIV PREVENTION AND TREATMENT EFFORTS IN BRAZIL AND THE REGION 

Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

FIRESIDE CHAT WITH ROCHELLE WALENSKY

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

11:00 AM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT TECHNICAL WORKSHOPS

FRONTIERS IN LABORATORY TECHNOLOGIES

  • POPULATION-LEVEL VIRAL SEQUENCING – Tulio de Oliveira, University of KwaZulu-Natal, Durban, South Africa
  • AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN – Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA, USA
  • STUDYING VIRAL EVOLUTION TO UNDERSTAND VIRAL FITNESS AND IMMUNE EVASION – Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • SINGLE-CELL PROTEOMICS – Nikolai Slavov, Northeastern University, Boston, MA, USA

CASE-BASED LIVER WORKSHOP

  • GETTING HEPATITIS C AGAIN – Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands
  • STEATOSIS IN PERSONS LIVING WITH HIV – Maud Lemoine, Imperial College London, London, United Kingdom
  • CONTROVERSIES IN HEPATITIS B – Chloe L. Thio, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • THE ORIGINAL DELTA VIRUS – Markus Cornberg, Medizinische Hochschule Hannover, Hannover, Germany

CLINICAL TRIAL DESIGN AND ANALYSIS

  • ASSESSING VACCINE EFFICACY IN THE REAL WORLD – Sheena G. Sullivan, University of Melbourne, Melbourne, Australia
  • STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS? – Eric J. Rubin, New England Journal of Medicine, Boston, MA, USA
  • ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY – Peter Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
MONDAY PLENARY SESSION

HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

Michaela Müller-Trutwin, Institut Pasteur, Paris, France

CHILDREN EXPOSED TO HIV, BUT UNINFECTED: BALANCING THE SCALES

Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST-IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES

  • HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE – Margaret Stanley, University of Cambridge, Cambridge, United Kingdom
  • FLU VACCINES: THE GLASS HALF-FULL – Florian Krammer, Columbia University, New York, NY, USA
  • HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES – Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA
  • IMMUNE ESCAPE BY HIV: OLD CONCEPTS AND NEW DATA – Alexandra Trkola, University of Zurich, Zurich, Switzerland
  • UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC – John P. Moore, Weill Cornell Medical College, New York, NY, USA

COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

Case presentations with a discussion by the expert panel and questions from the audience. 

Moderators: Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA, and Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

Panelists: 

  • Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
  • Laura E. Riley, Weill Cornell Medicine, New York, NY, USA
  • David Lye, National Centre for Infectious Diseases, Singapore
  • Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

Presentations followed by a panel discussion and questions from the audience.

  • VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES – Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA
  • VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS – Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA
  • LEGAL AND POLITICAL BARRIERS TO MANDATES IN THE UNITED STATES, AND SOLUTIONS FOR OVERCOMING THEM – Lawrence O. Gostin, Georgetown University, Washington, DC, USA
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

  • STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION – Dmitry Lyumkis, Salk Institute for Biological Sciences, La Jolla, CA, USA
  • VIEWING THE VIRAL CAPSID LIKE NEVER BEFORE – John Briggs, Max Planck Institute of Biochemistry, Martinsried, Germany
  • NEW ROLE FOR INTEGRASE IN VIRAL MATURATION – Sebla B. Kutluay, Washington University in St Louis, Saint Louis, MO, USA

INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

  • SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS – Claire Thorne, University College London, London, United Kingdom
  • ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES – Martina Penazzato, World Health Organization, Geneva, Switzerland
  • SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN – Adrie Bekker, Stellenbosch University, Cape Town, South Africa

BRINGING CHOICE TO HIV PREVENTION

  • PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? – Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA 
  • WHY DON’T YOU JUST USE WHAT WE TELL YOU TO USE? PERSPECTIVES ON CHOICE – Kenyon Farrow, PrEP4ALL, New York, NY, USA
  • APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP – Dominika Seidman, University of California San Francisco, San Francisco, CA, USA
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
TUESDAY PLENARY SESSION

NEW INSIGHTS INTO HIV RNA BIOLOGY

Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA

UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

Muge Cevik, University of St Andrews, St Andrews, United Kingdom

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

Presentations followed by a panel discussion and questions from the audience.

  • OVERVIEW AND CONTEXT FROM THE PATIENT CARE PERSPECTIVE – Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA
  • THEMES IN NEUROLOGY – Avindra Nath, National Institutes of Health, Bethesda, MD, USA
  • THEMES IN VIROLOGY – Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA
  • THEMES IN IMMUNOLOGY – Akiko Iwasaki, Yale University, New Haven, CT, USA

WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

Presentations followed by a panel discussion and questions from the audience.

  • GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN – Rachel Baggaley, World Health Organization, Geneva, Switzerland
  • EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP – James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya
  • PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN – Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE – Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

  • SHAPING AND QUANTIFYING THE HIV RESERVOIR – Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia
  • ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVIOR – Francesco R. Simonetti, Johns Hopkins University, Baltimore, MD, USA
  • NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS – Mirko Paiardini, Emory University, Atlanta, GA, USA

ALL THINGS TB

  • TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT? – Susan Dorman, Medical University of South Carolina, Charleston, SC, USA
  • NEW APPROACHES TO TREATMENT SHORTENING FOR MULTIDRUG AND EXTENSIVELY DRUG RESISTANT – David Moore, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • THE PROMISE OF LONG-ACTING INJECTABLE DRUGS AND NEW AGENTS FOR TREATMENT OF TB – Eric L. Nuermberger, Johns Hopkins University, Baltimore, MD, USA

SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

  • THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES – Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • CURRENT AND FUTURE RESEARCH IN STI VACCINES – Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • IS STI PrEP THE ANSWER? – Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
WEDNESDAY PLENARY SESSION

NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

Chloe Orkin, Queen Mary University of London, London, United Kingdom

PAST AND FUTURE OF HIV VACCINES

Mark Feinberg, International AIDS Vaccine Initiative (IAVI), Amsterdam, Netherlands

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

Presentations followed by a panel discussion and questions from the audience.

  • NEW AND IMPROVED T-CELL CARs FOR HIV ERADICATION OR CONTROL – James L. Riley, University of Pennsylvania, Philadelphia, PA, USA
  • GENERATING CAR T CELLS IN VIVO – Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, USA
  • NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA – Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • STIMULATING CARs WITH mRNA VACCINES – Benjamin Rengstl, BioNTech, Mainz, Germany

HIV CONTROVERSIES: APPROACH TO TREATMENT-EXPERIENCED PATIENTS

Case presentations with discussion by the expert panel and questions from the audience. 

Panelists

  • Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA
  • Annemarie Wensing, University Medical Center Utrecht, Utrecht, Netherlands
  • Timothy Wilkin, Weill Cornell Medicine, New York, NY, USA

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Presentations followed by a panel discussion and questions from the audience.

  • ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION – Arnaud Fontanet, Institut Pasteur, Paris, France
  • IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT? – Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA
  • ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE? – Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2 – Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, United Kingdom
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES

  • LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? – Carolyn Williamson, University of Cape Town, Cape Town, South Africa
  • PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS – Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA
  • JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH? – William R. Schief, Scripps Research Institute, La Jolla, CA, USA

HIV AND AGING

  • INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS – Kristine Erlandson, University of Colorado, Denver, CO, USA
  • COMORBIDITIES THAT ARE INCREASED (OR NOT) IN TREATED HIV – Mark Siedner, Harvard Medical School, Boston, MA, USA
  • POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV – Nicholas Funderburg, The Ohio State University, Columbus, OH, USA
  • Panelist – Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
  • Panelist – Venita Ray, Positive Women’s Network, Oakland, CA, USA

HIV PREVENTION IN SPECIAL POPULATIONS

  • A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE DRUGS – Adam W. Carrico, University of Miami, Miami, FL, USA
  • TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE – Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA
  • HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK – Frances Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe
Saturday, February 12, 2022
8:30 AM MT - 12:30 PM MT
In-Person
Virtual
SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

  • ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 – Theodora Hatziioannou, Rockefeller University, New York, NY, USA
  • ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY – Penny Moore, University of the Witwatersrand, Johannesburg, South Africa
  • ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC – Carlos del Rio, Emory University, Atlanta, GA, USA
  • ADVANCES IN BIOMEDICAL PREVENTION OF HIV – Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES – Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA
Sunday, February 13, 2022
8:30 AM MT - 10:45 AM MT
In-Person
Virtual
OPENING SESSION

MARTIN DELANEY PRESENTATION

WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, PrEPster, London, United Kingdom

The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.

BERNARD FIELDS LECTURE

Dan H. Barouch, Beth Israel Deaconess Medical Center, Boston, MA, USA

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

N’GALY-MANN LECTURE

HIV PREVENTION AND TREATMENT EFFORTS IN BRAZIL AND THE REGION 

Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

FIRESIDE CHAT WITH ROCHELLE WALENSKY

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

11:00 AM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT TECHNICAL WORKSHOPS

FRONTIERS IN LABORATORY TECHNOLOGIES

  • POPULATION-LEVEL VIRAL SEQUENCING – Tulio de Oliveira, University of KwaZulu-Natal, Durban, South Africa
  • AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN – Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA, USA
  • STUDYING VIRAL EVOLUTION TO UNDERSTAND VIRAL FITNESS AND IMMUNE EVASION – Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • SINGLE-CELL PROTEOMICS – Nikolai Slavov, Northeastern University, Boston, MA, USA

CASE-BASED LIVER WORKSHOP

  • GETTING HEPATITIS C AGAIN – Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands
  • STEATOSIS IN PERSONS LIVING WITH HIV – Maud Lemoine, Imperial College London, London, United Kingdom
  • CONTROVERSIES IN HEPATITIS B – Chloe L. Thio, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • THE ORIGINAL DELTA VIRUS – Markus Cornberg, Medizinische Hochschule Hannover, Hannover, Germany

CLINICAL TRIAL DESIGN AND ANALYSIS

  • ASSESSING VACCINE EFFICACY IN THE REAL WORLD – Sheena G. Sullivan, University of Melbourne, Melbourne, Australia
  • STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS? – Eric J. Rubin, New England Journal of Medicine, Boston, MA, USA
  • ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY – Peter Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Monday, February 14, 2022
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
MONDAY PLENARY SESSION

HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

Michaela Müller-Trutwin, Institut Pasteur, Paris, France

CHILDREN EXPOSED TO HIV, BUT UNINFECTED: BALANCING THE SCALES

Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST-IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES

  • HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE – Margaret Stanley, University of Cambridge, Cambridge, United Kingdom
  • FLU VACCINES: THE GLASS HALF-FULL – Florian Krammer, Columbia University, New York, NY, USA
  • HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES – Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA
  • IMMUNE ESCAPE BY HIV: OLD CONCEPTS AND NEW DATA – Alexandra Trkola, University of Zurich, Zurich, Switzerland
  • UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC – John P. Moore, Weill Cornell Medical College, New York, NY, USA

COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

Case presentations with a discussion by the expert panel and questions from the audience. 

Moderators: Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA, and Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

Panelists: 

  • Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
  • Laura E. Riley, Weill Cornell Medicine, New York, NY, USA
  • David Lye, National Centre for Infectious Diseases, Singapore
  • Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

Presentations followed by a panel discussion and questions from the audience.

  • VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES – Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA
  • VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS – Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA
  • LEGAL AND POLITICAL BARRIERS TO MANDATES IN THE UNITED STATES, AND SOLUTIONS FOR OVERCOMING THEM – Lawrence O. Gostin, Georgetown University, Washington, DC, USA
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

  • STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION – Dmitry Lyumkis, Salk Institute for Biological Sciences, La Jolla, CA, USA
  • VIEWING THE VIRAL CAPSID LIKE NEVER BEFORE – John Briggs, Max Planck Institute of Biochemistry, Martinsried, Germany
  • NEW ROLE FOR INTEGRASE IN VIRAL MATURATION – Sebla B. Kutluay, Washington University in St Louis, Saint Louis, MO, USA

INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

  • SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS – Claire Thorne, University College London, London, United Kingdom
  • ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES – Martina Penazzato, World Health Organization, Geneva, Switzerland
  • SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN – Adrie Bekker, Stellenbosch University, Cape Town, South Africa

BRINGING CHOICE TO HIV PREVENTION

  • PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? – Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA 
  • WHY DON’T YOU JUST USE WHAT WE TELL YOU TO USE? PERSPECTIVES ON CHOICE – Kenyon Farrow, PrEP4ALL, New York, NY, USA
  • APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP – Dominika Seidman, University of California San Francisco, San Francisco, CA, USA
Tuesday, February 15, 2022
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
TUESDAY PLENARY SESSION

NEW INSIGHTS INTO HIV RNA BIOLOGY

Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA

UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

Muge Cevik, University of St Andrews, St Andrews, United Kingdom

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

Presentations followed by a panel discussion and questions from the audience.

  • OVERVIEW AND CONTEXT FROM THE PATIENT CARE PERSPECTIVE – Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA
  • THEMES IN NEUROLOGY – Avindra Nath, National Institutes of Health, Bethesda, MD, USA
  • THEMES IN VIROLOGY – Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA
  • THEMES IN IMMUNOLOGY – Akiko Iwasaki, Yale University, New Haven, CT, USA

WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

Presentations followed by a panel discussion and questions from the audience.

  • GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN – Rachel Baggaley, World Health Organization, Geneva, Switzerland
  • EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP – James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya
  • PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN – Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE – Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

  • SHAPING AND QUANTIFYING THE HIV RESERVOIR – Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia
  • ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVIOR – Francesco R. Simonetti, Johns Hopkins University, Baltimore, MD, USA
  • NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS – Mirko Paiardini, Emory University, Atlanta, GA, USA

ALL THINGS TB

  • TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT? – Susan Dorman, Medical University of South Carolina, Charleston, SC, USA
  • NEW APPROACHES TO TREATMENT SHORTENING FOR MULTIDRUG AND EXTENSIVELY DRUG RESISTANT – David Moore, London School of Hygiene & Tropical Medicine, London, United Kingdom
  • THE PROMISE OF LONG-ACTING INJECTABLE DRUGS AND NEW AGENTS FOR TREATMENT OF TB – Eric L. Nuermberger, Johns Hopkins University, Baltimore, MD, USA

SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

  • THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES – Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • CURRENT AND FUTURE RESEARCH IN STI VACCINES – Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • IS STI PrEP THE ANSWER? – Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya
Wednesday, February 16, 2022
8:30 AM MT - 9:30 AM MT
In-Person
Virtual
WEDNESDAY PLENARY SESSION

NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

Chloe Orkin, Queen Mary University of London, London, United Kingdom

PAST AND FUTURE OF HIV VACCINES

Mark Feinberg, International AIDS Vaccine Initiative (IAVI), Amsterdam, Netherlands

9:45 AM MT - 11:45 AM MT
In-Person
Virtual
ORAL ABSTRACT SESSIONS

Oral Abstract Sessions will be announced January 2022

12:00 PM MT - 1:00 PM MT
In-Person
Virtual
CONCURRENT INTERACTIVE SESSIONS

CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

Presentations followed by a panel discussion and questions from the audience.

  • NEW AND IMPROVED T-CELL CARs FOR HIV ERADICATION OR CONTROL – James L. Riley, University of Pennsylvania, Philadelphia, PA, USA
  • GENERATING CAR T CELLS IN VIVO – Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, USA
  • NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA – Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • STIMULATING CARs WITH mRNA VACCINES – Benjamin Rengstl, BioNTech, Mainz, Germany

HIV CONTROVERSIES: APPROACH TO TREATMENT-EXPERIENCED PATIENTS

Case presentations with discussion by the expert panel and questions from the audience. 

Panelists

  • Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA
  • Annemarie Wensing, University Medical Center Utrecht, Utrecht, Netherlands
  • Timothy Wilkin, Weill Cornell Medicine, New York, NY, USA

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Presentations followed by a panel discussion and questions from the audience.

  • ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION – Arnaud Fontanet, Institut Pasteur, Paris, France
  • IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT? – Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA
  • ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE? – Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2 – Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, United Kingdom
2:30 PM MT - 4:00 PM MT
In-Person
POSTER SESSIONS

Poster Sessions will be released January 2022

4:00 PM MT - 5:30 PM MT
In-Person
CONCURRENT SYMPOSIA

IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES

  • LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? – Carolyn Williamson, University of Cape Town, Cape Town, South Africa
  • PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS – Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA
  • JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH? – William R. Schief, Scripps Research Institute, La Jolla, CA, USA

HIV AND AGING

  • INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS – Kristine Erlandson, University of Colorado, Denver, CO, USA
  • COMORBIDITIES THAT ARE INCREASED (OR NOT) IN TREATED HIV – Mark Siedner, Harvard Medical School, Boston, MA, USA
  • POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV – Nicholas Funderburg, The Ohio State University, Columbus, OH, USA
  • Panelist – Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
  • Panelist – Venita Ray, Positive Women’s Network, Oakland, CA, USA

HIV PREVENTION IN SPECIAL POPULATIONS

  • A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE DRUGS – Adam W. Carrico, University of Miami, Miami, FL, USA
  • TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE – Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA
  • HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK – Frances Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe